In a survey of nearly 1,200 recent cancer patients and survivors conducted as part of the American Cancer Society Cancer Action Network’s Survivor Views project, more than 80% of respondents said they would be willing to use remote technologies and tools in a trial.
FDA has announced that the agency will begin immediately reviewing all new clinical trials that include shipping American citizens’ living cells to “China and other hostile countries for genetic engineering and subsequent infusion” back into American patients.
